Ecstasy's Rebuff as PTSD Therapy Exposes Sloppy Processes at FDA [BNN Bloomberg (Canada)]
Mind Medicine (MindMed) Inc. - Common Shares (MNMD)
Company Research
Source: BNN Bloomberg
Supporters had hoped a positive outcome for Lykos Therapeutics Inc.'s treatment for post-traumatic stress disorder would advance efforts to legalize psychedelics for medical use. Instead, a committee of outside experts convened by the US Food and Drug Administration to review the treatment had sharp criticism about the study design approved by FDA, calling into question the agency's credibility and whether it will be ready to green-light any psychedelic drugs in the near future. “The committee rightly identified a number of significant concerns regarding the nature of the data that was presented,” said Caleb Alexander, a professor of epidemiology and medicine at Johns Hopkins University. “The FDA is going to continue to have to grapple with assessing the safety and effectiveness of psychedelics.” Jefferies analyst Andrew Tsai said the setback at Tuesday's meeting may result in “some increased uncertainty around the approvability of psychedelics.” While some of the concerns were
Show less
Read more
Impact Snapshot
Event Time:
MNMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MNMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MNMD alerts
High impacting Mind Medicine (MindMed) Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
MNMD
News
- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- MindMed to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual ConferenceBusiness Wire
- MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)Business Wire
- Psychedelics Stocks Are Falling After a Shocking Vote at the FDA. Here's What You Need to Know. [Yahoo! Finance]Yahoo! Finance
- Mind Medicine (MindMed) Inc.'s (NASDAQ:MNMD) 18% loss last week hit both individual investors who own 46% as well as institutions [Yahoo! Finance]Yahoo! Finance
MNMD
Earnings
- 5/8/24 - Miss
MNMD
Sec Filings
- 6/25/24 - Form 4
- 6/25/24 - Form 4
- 6/25/24 - Form 4
- MNMD's page on the SEC website